Correlation between Circulating Endothelial Progenitor Cell Markers, Vitamin D, and Iron Levels in Diabetic Nephropathy

Pouresmaeil, Vahid; Jasem, Moslem; Maktoof, Mostafa; Rabani Nia, Tayebeh; Homayouni Tabrizi, Masoud

doi:10.18502/ijdo.v16i1.15240

Volume 16, Issue 1 (3-2024) IJDO 2024, 16(1): 32-41 | Back to browse issues page

‎ 10.18502/ijdo.v16i1.15240

Mendeley

Zotero

RefWorks

Pouresmaeil V, Jasem M, Maktoof M, Rabani Nia T, Homayouni Tabrizi M. Correlation between Circulating Endothelial Progenitor Cell Markers, Vitamin D, and Iron Levels in Diabetic Nephropathy. IJDO 2024; 16 (1) :32-41
URL: http://ijdo.ssu.ac.ir/article-1-853-en.html

Correlation between Circulating Endothelial Progenitor Cell Markers, Vitamin D, and Iron Levels in Diabetic Nephropathy

Vahid Pouresmaeil ^*

, Moslem Jasem

, Mostafa Maktoof

, Tayebeh Rabani Nia

, Masoud Homayouni Tabrizi

1Department of Biochemistry, Faculty of Medicine, Mashhad Medical Sciences, Islamic Azad University, Mashhad, Iran. 2Innovative Medical Research Center Faculty of Medicine, Mashhad Medical Sciences, Islamic Azad University, Mashhad, Iran.

Abstract: (286 Views)

Objective: Circulating endothelial progenitor cells (EPCs) play an essential role in endothelial repair and neovascularization. Vitamin D deficiency may contribute to EPC depletion and endothelial dysfunction in patients with type 2 diabetes. In addition, iron overload is closely related to the development of diabetes and its various chronic complications. This study was designed to determine the relationship between EPC markers (CD34, CD133), vitamin D, and iron in patients with diabetic nephropathy.
Materials and Methods: This case-control study was conducted on 67 diabetic patients with or without nephropathy. Blood pressure and all biochemical parameters were measured and compared. Serum concentrations of insulin, vitamin D, CD34, and CD133 were measured using ELISA. Serum iron concentration was measured using atomic absorption spectrometry.
Results: Body mass index (P= 0.006), diastolic pressure (P= 0.018), insulin level (P= 0.028), Creatinine (P= 0.013), duration of diabetes, uric acid, and glomerular filtration rate (GFR) were significantly different between the two groups (each P= 0.0001).The vitamin D (P= 0.034), CD34 (P= 0.0001), and CD133 (P= 0.025) levels decreased, and Iron (P= 0.0001) increased in the case group. Also, CD34 has a significant direct relationship with insulin, insulin resistance, and CD133. The results showed that vitamin D, iron, CD34, and CD133 had a significant relationship with the severity of nephropathy (P= 0.0001, each).
Conclusion: Increased iron levels and decreased vitamin D, CD34, and CD133 levels are associated with the severity of nephropathy. This result indicates that diabetic nephropathy may directly reduce CD34 and CD133 levels in the body, increasing the incidence of secondary complications in these patients.

Keywords: Diabetic nephropathy, Vitamin D, CD34 antigen, CD133 antigen, Iron

Full-Text [PDF 257 kb] (127 Downloads)

Type of Study: Research | Subject: Special
Received: 2023/10/8 | Accepted: 2024/01/10 | Published: 2024/03/20

References

1. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G, Rubino F. Bariatric surgery versus conventional medical therapy for type 2 diabetes. New England Journal of Medicine. 2012;366(17):1577-85.

2. Teufel F, Seiglie JA, Geldsetzer P, Theilmann M, Marcus ME, Ebert C, et al. Body-mass index and diabetes risk in 57 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data in 685 616 adults. The Lancet. 2021;398(10296):238-48.

3. Khamseh ME, Sepanlou SG, Hashemi-Madani N, Joukar F, Mehrparvar AH, Faramarzi E, et al. Nationwide prevalence of diabetes and prediabetes and associated risk factors among Iranian adults: analysis of data from PERSIAN cohort study. Diabetes Therapy. 2021;12:2921-38.

4. Kanwar YS, Sun L, Xie P, Liu FY, Chen S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annual Review of Pathology: Mechanisms of Disease. 2011;6:395-423.

5. Alwan A. Global status report on noncommunicable diseases 2010. World Health Organization; 2011.

6. Rule AD, Gussak HM, Pond GR, Bergstralh EJ, Stegall MD, Cosio FG, et al. Measured and estimated GFR in healthy potential kidney donors. American Journal of Kidney Diseases. 2004 Jan 1;43(1):112-9.

7. Gross JL, De Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes care. 2005;28(1):164-76.

8. Reutens AT, Atkins RC. Epidemiology of diabetic nephropathy. Diabetes and the Kidney. 2011;170:1-7.

9. Dabla PK. Renal function in diabetic nephropathy. World journal of diabetes. 2010 May 5;1(2):48-56.

10. Kayaniyil S, Vieth R, Retnakaran R, Knight JA, Qi Y, Gerstein HC, et al. Association of vitamin D with insulin resistance and β-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes care. 2010;33(6):1379-81.

11. Pouresmaeil V, Ebre S, Yazdi MS. Assessment of the Relationship Between CD34 Antigen and Vitamin D Level and Insulin Resistance in Patients With Type 2 Diabetes. Clinical Diabetes. 2022;40(4):425-33.

12. Pouresmaeil V, Mashayekhi S, Sarafraz Yazdi M. Investigation of serum level relationship anti-glutamic acid decarboxylase antibody and inflammatory cytokines (IL1-β, IL-6) with vitamins D in type 2 diabetes. Journal of Diabetes & Metabolic Disorders. 2022;21(1):181-7.

13. Zhang Y, Deb DK, Kong J, Ning G, Wang Y, Li G, et al. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. American Journal of Physiology-Renal Physiology. 2009;297(3):F791-801.

14. Gagnon C, Lu ZX, Magliano DJ, Dunstan DW, Shaw JE, Zimmet PZ, et al. Serum 25-hydroxyvitamin D, calcium intake, and risk of type 2 diabetes after 5 years: results from a national, population-based prospective study (the Australian Diabetes, Obesity and Lifestyle study). Diabetes care. 2011;34(5):1133-8.

15. Mohammadian S, Fatahi N, Zaeri H, Vakili MA. Effect of vitamin d3 supplement in glycemic control of pediatrics with type 1 diabetes mellitus and vitamin d deficiency. Journal of clinical and diagnostic research:JCDR. 2015;9(3):SC05.

16. Dominguez JH, Liu Y, Kelly KJ. Renal iron overload in rats with diabetic nephropathy. Physiological Reports. 2015;3(12):e12654.

17. Vöö S, Dunaeva M, Eggermann J, Stadler N, Waltenberger J. Diabetes mellitus impairs CD133+ progenitor cell function after myocardial infarction. Journal of internal medicine. 2009;265(2):238-49.

18. Mohammad G, Vandooren J, Siddiquei MM, Martens E, El-Asrar AM, Opdenakker G. Functional links between gelatinase B/matrix metalloproteinase-9 and prominin-1/CD133 in diabetic retinal vasculopathy and neuropathy. Progress in retinal and eye research. 2014;43:76-91.

19. Dore FJ, Domingues CC, Ahmadi N, Kundu N, Kropotova Y, Houston S, et al. The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial. Cardiovascular diabetology. 2018;17(1):1-3.

20. Makino H, Miyamoto Y, Kikuchi‐Taura A, Soma T, Taguchi A, Kishimoto I. Decreased levels of circulating CD 34+ cells are associated with coronary heart disease in Japanese patients with type 2 diabetes. Journal of Diabetes Investigation. 2015;6(4):473-8.

21. Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney international. 2021;100(4):753-79. [DOI:10.1016/j.kint.2021.05.015]

22. Khoury M, Manlhiot C, McCrindle BW. Role of the waist/height ratio in the cardiometabolic risk assessment of children classified by body mass index. Journal of the American College of Cardiology. 2013;62(8):742-51.

23. Hollis BW, Horst RL. The assessment of circulating 25 (OH) D and 1, 25 (OH) 2D: where we are and where we are going. The Journal of steroid biochemistry and molecular biology. 2007;103(3-5):473-6.

24. Siniscalchi A, Cucchetti A, Miklosova Z, Lauro A, Zanoni A, Spedicato S, et al. Post‐reperfusion syndrome during isolated intestinal transplantation: outcome and predictors. Clinical transplantation. 2012;26(3):454-60.

25. Seedat YK, Rayner BL. South african hypertension guideline 2011: guideline. South African Medical Journal. 2012;102(1):60-83.

26. Krolewski AS, Skupien J, Rossing P, Warram JH. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney international. 2017;91(6):1300-11.

27. Luo YY, Zhao J, Han XY, Zhou XH, Wu J, Ji LN. Relationship between serum zinc level and microvascular complications in patients with type 2 diabetes. Chinese medical journal. 2015;128(24):3276-82.

28. Razi F, Nasli-Esfahani E, Bandarian F. Association of serum uric acid with nephropathy in Iranian type 2 diabetic patients. Journal of Diabetes & Metabolic Disorders. 2018;17:71-5.

29. Balla DI, Abdalla AM, Elrayah ZA, Abdrabo AA. The Association of 25 (OH) Vitamin D Level with glycemic control and nephropathy complication in Sudanese with Type 2 Diabetes. Health Sciences. 2018;7(2):62-8.

30. Xiao X, Wang Y, Hou Y, Han F, Ren J, Hu Z. Vitamin D deficiency and related risk factors in patients with diabetic nephropathy. Journal of International Medical Research. 2016;44(3):673-84.

31. Barbieri M, Ragno E, Benvenuti E, Zito GA, Corsi A, Ferrucci L, et al. New aspects of the insulin resistance syndrome: impact on haematological parameters. Diabetologia. 2001;44:1232-7.

32. Pouresmaeil V, Al Abudi AH, Mahimid AH, Sarafraz Yazdi M, Es-Haghi A. Evaluation of serum selenium and copper levels with inflammatory cytokines and indices of oxidative stress in type 2 diabetes. Biological Trace Element Research. 2023;201(2):617-26.

33. Tuleab SF, Abd-Allah SM, Abed MA. Evaluate the Plasma Iron Levels on Iraqi Type 2 Diabetic Nephropathy. Journal of university of Anbar for Pure science. 2017;11(1):9-13.

34. Hashemieh M, Azarkeivan A, Akhlaghpoor S, Shirkavand A, Sheibani K. T2-star (T2*) magnetic resonance imaging for assessment of kidney iron overload in thalassemic patients. Archives of Iranian Medicine.2012;15(2):91-4.

35. Martines AM, Masereeuw R, Tjalsma H, Hoenderop JG, Wetzels JF, Swinkels DW. Iron metabolism in the pathogenesis of iron-induced kidney injury. Nature Reviews Nephrology. 2013;9(7):385-98.

36. Rigato M, Bittante C, Albiero M, Avogaro A, Fadini GP. Circulating progenitor cell count predicts microvascular outcomes in type 2 diabetic patients. The Journal of Clinical Endocrinology & Metabolism. 2015;100(7):2666-72.

37. Dessapt C, Karalliedde J, Hernandez-Fuentes M, Martin PP, Maltese G, Dattani N, et al. Circulating vascular progenitor cells in patients with type 1 diabetes and microalbuminuria. Diabetes care. 2010;33(4):875-7.

38. Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, De Kreutzenberg S, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1α. Diabetes care. 2010;33(7):1607-9.

39. Boscari F, D'Anna M, Bonora BM, Tresso S, Cappellari R, Avogaro A, et al. Effects of glucose variability on hematopoietic stem/progenitor cells in patients with type 1 diabetes. Journal of Endocrinological Investigation. 2021;44:119-26.